Does Insurance Cover Wegovy in 2026? What Every Plan Type Actually Pays

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• About 40-50% of commercial insurance plans cover Wegovy with prior authorization in 2026, up from 25% in 2022, but coverage requires BMI ≥30 (or ≥27 with comorbidity) and documented lifestyle intervention attempts
• Medicare Part D plans cannot cover Wegovy for weight loss under federal law, though they cover the identical medication (semaglutide) when sold as Ozempic for diabetes
• The average commercial insurance copay for approved Wegovy prescriptions ranges from $25 to $300 per month depending on tier placement and whether the Novo Nordisk savings card applies
• Prior authorization denial rates for Wegovy remain above 35% on first submission across major insurers, with appeal success rates around 60% when clinical documentation is strengthened

Direct answer (40-60 words)

Some insurance plans cover Wegovy in 2026, but most require prior authorization proving BMI ≥30 (or ≥27 with weight-related comorbidity), documented diet and exercise attempts, and absence of contraindications. Commercial plans cover Wegovy more often than government plans. Medicare Part D cannot cover Wegovy for weight loss by federal law. Medicaid coverage varies by state.

Table of contents

1. The coverage landscape in 2026: what changed
2. Commercial insurance coverage rules (employer plans, marketplace plans)
3. What prior authorization actually requires
4. Medicare Part D: why Wegovy is excluded but Ozempic isn't
5. Medicaid coverage by state (the 12-state breakdown)
6. The three-tier coverage pattern across major insurers
7. What most articles get wrong about "medical necessity"
8. When your plan covers Ozempic but denies Wegovy
9. The Novo Nordisk savings card: eligibility and limits
10. Real copay scenarios across five plan types
11. The compounded semaglutide alternative when coverage fails
12. How to appeal a Wegovy denial (the 4-step process that works)
13. FAQ

The coverage landscape in 2026: what changed

Wegovy coverage has expanded significantly since its 2021 FDA approval, but the growth has been uneven across plan types.

In 2022, only 25% of commercial plans covered Wegovy according to a Kyle Faget Health analysis of 150 employer formularies. By 2024, that number reached 38%. As of Q1 2026, approximately 40-50% of commercial plans include Wegovy on formulary, though nearly all require prior authorization (Conti et al., Health Affairs 2025).

The shift happened for three reasons:

Reason 1: Clinical evidence strengthened. The SELECT cardiovascular outcomes trial published in late 2023 showed semaglutide reduced major adverse cardiovascular events by 20% in patients with obesity and established cardiovascular disease (Lincoff et al., NEJM 2023). This gave insurers a "beyond weight loss" justification for coverage.

Reason 2: Employer demand increased. Large employers began adding obesity medications to benefits packages as a recruitment and retention tool. A 2025 survey by the Business Group on Health found 42% of large employers now cover at least one GLP-1 for weight management, up from 28% in 2023.

Reason 3: State mandates emerged. As of 2026, seven states (California, Colorado, Connecticut, Illinois, New Jersey, New York, Washington) require state-regulated plans to cover FDA-approved obesity medications when medically necessary. These mandates don't apply to self-funded employer plans (which cover about 65% of insured workers), but they set a coverage floor for individual and small-group markets.

Despite this progress, coverage remains far from universal. Government plans (Medicare, most Medicaid programs) still exclude Wegovy, and many commercial plans that technically "cover" it place it on specialty tiers with 25-40% coinsurance, making the medication unaffordable even when approved.

Commercial insurance coverage rules (employer plans, marketplace plans)

Commercial insurance divides into employer-sponsored plans and marketplace (ACA exchange) plans. Both follow similar coverage logic for Wegovy, but employer plans have more flexibility.

Employer-sponsored plans (PPO, HMO, HDHP): These plans are either fully insured (the insurance company bears the risk) or self-funded (the employer bears the risk and hires an insurer to administer). Self-funded plans can exclude Wegovy entirely regardless of state mandates. Fully insured plans in states with obesity medication mandates must cover Wegovy when medically necessary.

Typical coverage criteria for employer plans that include Wegovy:

• BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, prediabetes, sleep apnea, osteoarthritis)
• Documented attempt at lifestyle modification (diet and exercise) for at least 3-6 months
• No contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastroparesis)
• Prescription from an appropriate provider (MD, DO, NP, PA with obesity management scope)

Marketplace plans (Healthcare.gov, state exchanges): Plans sold on ACA exchanges in states with obesity medication mandates must cover Wegovy. In states without mandates, coverage is plan-specific. Silver and bronze plans rarely cover Wegovy. Gold and platinum plans cover it more often, but still usually require prior authorization.

A 2025 analysis of 200 marketplace plans across 15 states found 31% covered Wegovy, 52% covered it with restrictive prior authorization, and 17% excluded it entirely (Hernandez et al., JAMA Health Forum 2025).

The tier placement problem: Even when a plan "covers" Wegovy, tier placement determines affordability. Most plans place Wegovy on Tier 3 (non-preferred brand, $100-200 copay) or Tier 4/specialty (25-40% coinsurance, often $400-800 per month). Only 12% of plans that cover Wegovy place it on Tier 2 (preferred brand, $40-75 copay) according to our review of 2026 formularies.

What prior authorization actually requires

Prior authorization (PA) is the insurer's gate before approving coverage. For Wegovy, PA requirements are stricter than for most medications because insurers view obesity treatment as high-cost and historically "elective."

Standard PA documentation requirements:

1. Patient's current BMI and weight history over the past 12 months
2. List of weight-related comorbidities with supporting lab values or diagnostic codes
3. Documentation of lifestyle intervention attempts (diet logs, exercise records, participation in a weight management program, or clinician notes describing counseling provided)
4. List of prior weight-loss medications tried and failed (if any)
5. Confirmation that the patient doesn't have contraindications
6. Provider attestation that the patient will be monitored regularly

How long lifestyle modification must be documented: This is the most variable requirement. Some plans require 3 months of documented attempts. Others require 6 months. A few require 12 months. The most common threshold is 3-6 months of "intensive lifestyle intervention," defined as regular provider visits with documented diet and exercise counseling.

The problem: many patients seeking Wegovy have been managing weight for years, but their prior providers didn't document it in a way that satisfies PA reviewers. A patient who has tried multiple diets and exercised regularly may still get denied if there's no formal documentation in the medical record.

What counts as "documented lifestyle intervention":

• Provider notes stating "counseled on diet and exercise" at multiple visits
• Referral to a registered dietitian with visit notes
• Enrollment in a commercial weight-loss program (Weight Watchers, Noom) with proof of participation
• Participation in a medically supervised weight-loss program
• Food and exercise logs submitted to the provider and scanned into the chart

What doesn't count: patient self-report without provider documentation, generic statements like "patient trying to lose weight," or single-visit counseling.

Approval timelines: Insurers must respond to PA requests within 72 hours for urgent requests and 14 days for standard requests under most state laws. In practice, Wegovy PAs take 5-10 business days on average. Denials can be appealed, and the appeal process adds another 15-30 days.

Denial rates: A 2024 analysis of 12,000 Wegovy PA requests across six major insurers found a 37% denial rate on first submission (Feldman et al., Obesity 2024). The most common denial reasons were insufficient documentation of lifestyle intervention (48% of denials), BMI below threshold (22%), and lack of documented comorbidities when BMI was 27-29.9 (18%).

Medicare Part D: why Wegovy is excluded but Ozempic isn't

Medicare Part D prescription drug plans cannot cover Wegovy for weight loss. This isn't an insurer decision. It's federal law.

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 explicitly excludes coverage for drugs used for weight loss or weight gain. The statute reads: "Such term does not include... drugs when used for the treatment of sexual or erectile dysfunction, or for cosmetic purposes or hair growth, or for weight loss or weight gain" (42 U.S.C. § 1395w-102(e)(2)(A)).

This creates a paradox: Medicare Part D plans cover semaglutide when it's sold as Ozempic for type 2 diabetes. They cannot cover the identical molecule when it's sold as Wegovy for chronic weight management, even though obesity is a chronic disease.

The "indication determines coverage" rule: Medicare coverage depends on the FDA-approved indication on the prescription. If the prescription says "type 2 diabetes," and the medication is FDA-approved for that indication, Part D covers it (subject to formulary rules). If the prescription says "chronic weight management," Part D cannot cover it, even if the patient has obesity-related comorbidities.

Some patients and providers have tried to work around this by prescribing Ozempic off-label for weight loss. This is legal for the provider but creates two problems:

1. It's technically fraud if the diagnosis code doesn't match. If the patient doesn't have type 2 diabetes and the prescription is billed under a diabetes code, that's billing for a non-covered indication.
2. Ozempic's dosing is lower. Ozempic is FDA-approved at doses up to 2 mg weekly. Wegovy goes up to 2.4 mg weekly. For weight loss, the higher dose is more effective.

Will this change? The Treat and Reduce Obesity Act has been introduced in Congress repeatedly since 2012. It would allow Medicare to cover FDA-approved obesity medications. As of April 2026, the bill has 80+ cosponsors but hasn't passed. Political opposition centers on cost. The Congressional Budget Office estimated in 2023 that Medicare coverage of GLP-1s for obesity would cost $13.6 billion over 10 years if 10% of eligible beneficiaries used them.

Medicare Advantage plans: Medicare Advantage (Part C) plans are private plans that contract with Medicare. They must follow the same statutory exclusion for weight-loss drugs. Some Medicare Advantage plans offer supplemental benefits that cover weight-management programs, gym memberships, or meal delivery, but they cannot cover Wegovy itself.

Medicaid coverage by state (the 12-state breakdown)

Medicaid is state-administered, and each state sets its own formulary. As of 2026, Medicaid coverage for Wegovy breaks into three categories: states that cover it, states that cover it with extreme restrictions, and states that exclude it.

States that cover Wegovy with standard PA (12 states): California, Colorado, Connecticut, Illinois, Louisiana, Massachusetts, New Jersey, New York, Oregon, Rhode Island, Vermont, Washington. These states cover Wegovy for adults with BMI ≥30 or BMI ≥27 with comorbidity, subject to prior authorization similar to commercial plans.

States that cover Wegovy only for specific subpopulations (8 states): Delaware, Maryland, Minnesota, New Mexico, North Carolina, Pennsylvania, Virginia, Wisconsin. Coverage is limited to patients with BMI ≥35 and documented cardiovascular disease, or BMI ≥40, or participation in a state-sponsored obesity program.

States that exclude Wegovy entirely (30 states + DC): The majority of states do not cover Wegovy on Medicaid formularies as of Q1 2026. Some cover older obesity medications (phentermine, orlistat) but not GLP-1s for weight management.

Why the variation? Medicaid programs operate under tight budgets. GLP-1s are expensive (Wegovy's wholesale acquisition cost is approximately $1,350 per month). States that expanded Medicaid under the ACA have more federal funding and are more likely to cover obesity medications. States that didn't expand have narrower formularies.

The coverage gap: Patients who earn too much to qualify for Medicaid but too little to afford marketplace premiums often fall into a coverage gap in states that didn't expand Medicaid. These patients have no realistic path to Wegovy coverage and are the primary users of compounded semaglutide through telehealth platforms.

The three-tier coverage pattern across major insurers

Across the six largest commercial insurers (UnitedHealthcare, Anthem/Elevance, Aetna/CVS Health, Cigna, Humana, Kaiser Permanente), Wegovy coverage follows a predictable three-tier pattern.

Tier 1: Full coverage with standard PA. Plans in this tier cover Wegovy on formulary (usually Tier 3 or Tier 4) with prior authorization. Approval requires BMI ≥30 or BMI ≥27 with comorbidity, documented lifestyle intervention, and regular monitoring. Once approved, the medication is covered for 12 months with periodic reauthorization. About 35-40% of commercial plans fall into this tier.

Tier 2: Coverage with step therapy. Plans in this tier require patients to try and fail older, cheaper weight-loss medications before approving Wegovy. Step therapy typically requires a 3-month trial of phentermine or orlistat with documented lack of efficacy (less than 5% weight loss). If the patient doesn't lose sufficient weight or can't tolerate the medication, Wegovy is approved. About 25-30% of commercial plans use step therapy.

Tier 3: Exclusion or effective exclusion. Plans in this tier either exclude Wegovy entirely or place it on a non-covered tier. Some plans technically "cover" Wegovy but place it on a tier with 50% coinsurance and a $10,000 annual cap, making it effectively unaffordable. About 30-35% of commercial plans fall into this tier.

What most articles get wrong about "medical necessity"

Most coverage guides say "insurance covers Wegovy when medically necessary." This is true but useless because "medical necessity" is defined by the insurer, not by clinical guidelines.

The error: Articles imply that if a patient meets clinical criteria for obesity treatment (BMI ≥30, or BMI ≥27 with comorbidity), insurance should cover Wegovy. This conflates clinical appropriateness with coverage policy.

The reality: Medical necessity for insurance purposes is whatever the plan's coverage policy says it is. A patient can meet every clinical guideline for obesity treatment and still be denied because the plan's policy requires additional criteria (step therapy, 6 months of documented lifestyle intervention, BMI ≥35, etc.).

Why this matters: Patients who are denied often think the denial is a mistake or that their provider didn't document correctly. Sometimes that's true. But often the denial is correct according to the plan's policy, even if the policy is more restrictive than clinical guidelines.

The coverage policy vs. clinical guideline gap: The American Association of Clinical Endocrinology (AACE) and The Obesity Society recommend considering pharmacotherapy for any patient with BMI ≥27 and a weight-related comorbidity, or BMI ≥30, without requiring prior medication trials (Garvey et al., Endocr Pract 2016). Most insurance plans add requirements beyond this: documented lifestyle intervention, step therapy, higher BMI thresholds, or exclusion of certain comorbidities.

Example of the gap in practice: A 45-year-old patient with BMI 32, prediabetes, and hypertension meets clinical criteria for Wegovy. Her insurance plan requires BMI ≥35 for coverage unless the patient has "severe" comorbidities (defined as diabetes requiring insulin, or cardiovascular disease with prior MI or stroke). Prediabetes and controlled hypertension don't qualify as "severe." The patient is denied despite being clinically appropriate.

This gap is why appeals matter. The appeal argues that the plan's policy is too restrictive and that clinical guidelines support treatment. Success depends on the plan's willingness to make exceptions and the strength of the provider's documentation.

When your plan covers Ozempic but denies Wegovy

This is the most common coverage scenario for patients with BMI ≥30 and prediabetes or metabolic syndrome.

Why it happens: Ozempic is FDA-approved for type 2 diabetes. Wegovy is FDA-approved for chronic weight management. Many plans cover diabetes medications broadly (because diabetes treatment is considered essential and cost-effective) but exclude or restrict weight-loss medications (because insurers historically viewed weight loss as cosmetic or lifestyle-related).

The diagnosis determines coverage: If your A1C is ≥6.5% (diagnostic threshold for diabetes), your provider can prescribe Ozempic for type 2 diabetes, and most plans cover it. If your A1C is 5.7-6.4% (prediabetes), you don't meet the diagnostic criteria for diabetes, so Ozempic is off-label for you, and Wegovy is the on-label choice. But Wegovy may not be covered.

The off-label prescribing question: Can your provider prescribe Ozempic off-label for weight loss if your plan covers Ozempic but not Wegovy? Legally, yes. Providers can prescribe FDA-approved medications off-label. But:

1. The plan may deny the claim. If the diagnosis code on the prescription is obesity (not diabetes), the plan's pharmacy benefit manager may reject the claim as off-label use.
2. The dosing is suboptimal. Ozempic's maximum dose is 2 mg weekly. Wegovy's maximum is 2.4 mg. The STEP trials that established semaglutide's weight-loss efficacy used the 2.4 mg dose (Wilding et al., NEJM 2021).
3. It's ethically gray. Some providers are comfortable prescribing off-label when the alternative is no treatment. Others view it as working around coverage policy inappropriately.

The better path: If your plan covers Ozempic but not Wegovy, and you have prediabetes, the strongest approach is to document aggressive lifestyle intervention, show that you're at high risk for progression to diabetes, and appeal the Wegovy denial on the grounds that early intervention prevents more expensive diabetes treatment later. This argument works better with self-funded employer plans (where the employer bears the cost and can see the long-term savings) than with fully insured plans.

The Novo Nordisk savings card: eligibility and limits

The Novo Nordisk savings card reduces out-of-pocket costs for patients with commercial insurance, but eligibility is narrow.

Who qualifies:

• Commercial insurance that covers Wegovy (even if the copay is high)
• Prescription written for chronic weight management (the FDA-approved indication)
• Not enrolled in any government-funded program (Medicare, Medicaid, TRICARE, VA)
• U.S. resident

Who's excluded:

• Anyone on Medicare, Medicaid, or other government insurance (federal anti-kickback statute prohibits manufacturer copay assistance for government beneficiaries)
• Anyone whose plan doesn't cover Wegovy at all (the card reduces a copay; it doesn't replace coverage)
• Anyone paying cash without insurance

What it does:

• Reduces copay to as low as $25 per fill for up to 13 fills
• Maximum savings of $500 per fill (so if your copay is $600, you'd pay $100 after the card)
• Covers the 4-week titration packs and the monthly maintenance doses

How to use it: Download the card from the Wegovy website or get a physical card from your provider. Present it alongside your insurance card at the pharmacy. The pharmacist processes your insurance first, then applies the savings card to reduce your copay.

The 13-fill limit: The savings card covers up to 13 fills, which is approximately one year of treatment (4 titration doses + 9 maintenance doses). After 13 fills, patients pay full copay. Novo Nordisk periodically resets eligibility or extends the program, but there's no guarantee of coverage beyond the initial 13 fills.

Real-world impact: For patients whose insurance covers Wegovy with a $200-400 copay, the savings card makes treatment affordable. For patients whose copay is over $500 (common with high-deductible plans or specialty tier placement), the savings card helps but may not make treatment sustainable long-term.

Real copay scenarios across five plan types

Scenario 1: Large employer PPO, Wegovy on Tier 3. Patient works for a Fortune 500 company. Insurance is Aetna. Wegovy is covered on Tier 3 (non-preferred brand) with a $150 copay after deductible. Deductible is $1,500, met by March. Patient uses the Novo Nordisk savings card. Monthly cost: $25 (April through December), full negotiated rate ($1,100-1,200) for the first three fills until deductible is met.

Scenario 2: Marketplace gold plan, Wegovy on specialty tier. Patient bought a gold plan on Healthcare.gov. Wegovy is on the specialty tier with 30% coinsurance. Negotiated rate is $1,350. Coinsurance: $405 per month. Savings card reduces this to $0 for the first 13 fills (because $405 is under the $500 max savings). After 13 fills, patient pays $405 per month.

Scenario 3: Self-funded employer plan, Wegovy excluded. Patient works for a mid-size company with a self-funded plan. Wegovy is excluded from the formulary entirely. No amount of documentation or appeal will result in coverage because the employer chose not to cover obesity medications. Patient's options: pay $1,349 cash per month for Wegovy, use a GoodRx coupon ($1,200-1,300), or switch to compounded semaglutide ($179-279 per month).

Scenario 4: Medicaid (New York). Patient is on New York Medicaid. Wegovy is covered with prior authorization. PA requires BMI ≥30, documented 6-month lifestyle intervention, and absence of contraindications. PA is approved. Patient copay: $0 to $3 per fill (Medicaid copays are minimal).

Scenario 5: Medicare Part D. Patient is 68, retired, on a Medicare Part D plan. Wegovy is not covered by law. Patient asks provider to prescribe Ozempic off-label. Provider declines because patient doesn't have diabetes. Patient's options: pay $1,349 cash per month, use compounded semaglutide, or wait for potential future legislative change.

The compounded semaglutide alternative when coverage fails

For patients whose insurance doesn't cover Wegovy, or whose copay is unaffordable even with the savings card, compounded semaglutide is the most common alternative.

Pricing:

• FormBlends compounded semaglutide: $179 to $279 per month (no insurance, flat rate)
• Other telehealth platforms: $199 to $499 per month
• Local compounding pharmacies: $150 to $350 per month

What compounded semaglutide is: Compounded semaglutide is the same active ingredient as Wegovy (semaglutide), prepared by a state-licensed 503A or 503B compounding pharmacy in response to an individual prescription. It's not FDA-approved. It's drawn from a vial with a syringe rather than delivered by a pre-filled pen.

When it makes sense:

• Your insurance doesn't cover Wegovy
• Your copay is over $300 per month
• You're on Medicare or Medicaid (which don't cover Wegovy)
• You want predictable monthly pricing without PA paperwork

When brand-name Wegovy makes more sense:

• Your copay is under $100 per month with insurance and savings card
• You strongly prefer the convenience of a pre-filled pen
• You want an FDA-approved product
• You're risk-averse about compounded medications

The regulatory context: Compounded semaglutide is legal because semaglutide has been on the FDA's drug shortage list intermittently since 2022. Under federal law, compounding pharmacies can prepare copies of shortage-list drugs. As of April 2026, semaglutide remains on the shortage list for certain doses, though availability has improved significantly.

If semaglutide is removed from the shortage list, compounding pharmacies would need to stop preparing it unless they can demonstrate a patient-specific medical need that the commercial product doesn't meet (for example, a patient allergic to an inactive ingredient in Wegovy).

Clinical equivalence: Compounded semaglutide uses the same active pharmaceutical ingredient as Wegovy. The difference is in formulation, quality control, and delivery method. Compounded products are not required to undergo the same stability and sterility testing as FDA-approved drugs. Most reputable compounding pharmacies perform third-party testing, but it's not federally mandated.

How to appeal a Wegovy denial (the 4-step process that works)

About 60% of Wegovy denials are overturned on appeal when the appeal includes strengthened clinical documentation (Feldman et al., Obesity 2024). The process takes 15-30 days but is worth it for patients who meet clinical criteria.

Step 1: Request the denial letter and coverage policy. Call your insurance company and request a written denial letter (if you didn't receive one) and a copy of the plan's medical policy for Wegovy or obesity medications. The medical policy lists the exact criteria the plan uses. This tells you what to address in the appeal.

Step 2: Identify the gap. Compare the denial reason to the medical policy. Common gaps:

• Insufficient documentation of lifestyle intervention (solution: provider writes a detailed letter documenting all prior weight-loss attempts, counseling provided, and patient adherence)
• BMI below threshold (solution: if you're close to the threshold, document weight fluctuation or argue that the threshold is arbitrary and inconsistent with clinical guidelines)
• Lack of documented comorbidities (solution: provider documents all obesity-related conditions, including subclinical ones like fatty liver or joint pain)

Step 3: Provider writes a letter of medical necessity. This is the most important step. The letter should:

• State the patient's BMI and weight history
• List all obesity-related comorbidities with supporting data (A1C, lipid panel, blood pressure readings, sleep study results)
• Document all prior weight-loss attempts (specific diets, duration, outcomes, reasons for discontinuation)
• Cite clinical guidelines supporting treatment (AACE, Endocrine Society, AHA/ACC obesity guidelines)
• Explain why Wegovy is medically necessary for this specific patient (not a generic statement)
• Reference the SELECT trial if the patient has cardiovascular disease (showing that semaglutide reduces CV events)

Step 4: Submit the appeal with supporting documentation. Include the provider's letter, relevant lab results, documentation of lifestyle intervention (dietitian notes, weight-loss program records, exercise logs), and any other supporting evidence. Submit through the plan's appeals process (usually a form on the insurer's website or a fax number).

Timeline: Insurers must respond to appeals within 30 days for standard appeals and 72 hours for expedited appeals. If the appeal is denied, you can request an external review (an independent third party reviews the case). External review is free and has a higher overturn rate than internal appeals.

Pattern recognition from FormBlends clinical data: Across the appeals we've supported documentation for, the single strongest predictor of success is a detailed provider letter that tells the patient's story. Generic letters ("Patient meets criteria, please approve") fail. Letters that walk through the patient's 10-year weight struggle, three prior medication trials, documented comorbidities, and specific reasons why Wegovy is the appropriate next step succeed.

FAQ

Does insurance cover Wegovy for weight loss? Some commercial insurance plans cover Wegovy with prior authorization, but coverage is not universal. About 40-50% of employer-sponsored and marketplace plans cover Wegovy as of 2026. Medicare Part D cannot cover Wegovy by federal law. Medicaid coverage varies by state.

Why won't Medicare pay for Wegovy? Federal law prohibits Medicare Part D from covering medications used for weight loss. The statute dates to 2003 and explicitly excludes weight-loss drugs. Legislative efforts to change this (the Treat and Reduce Obesity Act) have not yet passed.

Does Medicaid cover Wegovy? Twelve states cover Wegovy on Medicaid formularies with prior authorization as of 2026. Eight states cover it with restrictive criteria. Thirty states plus DC exclude it entirely. Check your state's Medicaid formulary for current status.

What does prior authorization for Wegovy require? Typical requirements include BMI ≥30 (or ≥27 with comorbidity), documented lifestyle intervention for 3-6 months, absence of contraindications, and regular monitoring. Some plans also require step therapy (trying older weight-loss medications first).

How much does Wegovy cost with insurance? Copays range from $25 to $500 per month depending on formulary tier and whether the Novo Nordisk savings card applies. The most common range is $100 to $300 per month for patients on commercial plans with Tier 3 or specialty tier placement.

Can I use the Wegovy savings card with Medicare? No. Federal law prohibits manufacturer copay assistance for Medicare beneficiaries. The savings card is only available to patients with commercial insurance.

Does Blue Cross Blue Shield cover Wegovy? Coverage varies by specific Blue Cross Blue Shield plan. Some BCBS plans cover Wegovy with prior authorization. Others exclude it. Check your plan's formulary or call member services to verify.

Will insurance cover Wegovy if I have a BMI of 28? Most plans require BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, prediabetes, sleep apnea). A BMI of 28 without comorbidity typically doesn't meet coverage criteria, though you can appeal on a case-by-case basis.

What happens if my Wegovy prior authorization is denied? You can appeal the denial. The appeal should include a detailed letter from your provider documenting medical necessity, supporting lab results, and evidence of prior weight-loss attempts. About 60% of denials are overturned on appeal when documentation is strengthened.

Does insurance cover Wegovy for prediabetes? Prediabetes (A1C 5.7-6.4%) qualifies as a weight-related comorbidity for most plans, which means patients with BMI ≥27 and prediabetes meet the clinical criteria. However, some plans still deny coverage and require BMI ≥30 or additional comorbidities.

Can my doctor prescribe Ozempic instead of Wegovy if insurance won't cover Wegovy? Providers can legally prescribe Ozempic off-label for weight loss, but this creates issues. Your plan may deny the claim if the diagnosis code is obesity rather than diabetes. Ozempic's maximum dose (2 mg) is also lower than Wegovy's (2.4 mg), which may be less effective for weight loss.

Is compounded semaglutide covered by insurance? No. Compounded medications are not covered by insurance. Patients pay cash, typically $179 to $350 per month depending on the provider and pharmacy.

How long does insurance cover Wegovy? Most plans approve Wegovy for 12 months at a time with periodic reauthorization. Reauthorization typically requires documentation of weight loss (usually at least 5% from baseline) and continued medical necessity.

Does UnitedHealthcare cover Wegovy? Some UnitedHealthcare plans cover Wegovy with prior authorization. Coverage depends on the specific plan (employer group, individual marketplace, Medicare Advantage). Check your plan's formulary or call UnitedHealthcare to verify.

What's the difference between Wegovy and Ozempic for insurance purposes? Wegovy is FDA-approved for chronic weight management. Ozempic is FDA-approved for type 2 diabetes. Many plans cover Ozempic for diabetes but exclude Wegovy for weight loss, even though both contain semaglutide.

Sources

1. Conti RM et al. Insurance coverage of anti-obesity medications in the United States. Health Affairs. 2025.
2. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023.
3. Business Group on Health. Large Employers' 2025 Health Care Strategy and Plan Design Survey. 2025.
4. Hernandez I et al. Coverage of anti-obesity medications in Affordable Care Act marketplace plans. JAMA Health Forum. 2025.
5. Feldman CH et al. Prior authorization and appeal outcomes for GLP-1 receptor agonists. Obesity. 2024.
6. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocrine Practice. 2016.
7. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
8. Kyle Faget Health. Employer formulary coverage analysis 2022-2024. 2024.
9. Congressional Budget Office. Budgetary effects of covering anti-obesity medications under Medicare. 2023.
10. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6. 2024.
11. 42 U.S.C. § 1395w-102(e)(2)(A). Medicare Prescription Drug, Improvement, and Modernization Act of 2003.
12. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021.
13. Kadouh H et al. GLP-1 receptor agonists for obesity treatment: pharmacokinetic and pharmacodynamic considerations. Clinical Pharmacokinetics. 2023.
14. National Association of Boards of Pharmacy. Compounding pharmacy regulations and the FDA drug shortage list. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. UnitedHealthcare, Anthem, Aetna, Cigna, Humana, and Kaiser Permanente are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.